Researchers have potentially found a cure for the incurable disease SLE. Will it be successful?
FREMONT, CA: Systemic lupus erythematosus (SLE) is one of the potent autoimmune diseases which attack healthy parts of the body. The trial, TULIP 2, assessed AstraZeneca’s anifrolumab and obtained a clinically meaningful and statistically significant reduction in disease activity as compared to placebo, with both the arms getting standard of care.
Between 60 percent to 80 percent of adults having SLE displayed an increased number of genes induced with interferon, thus reflecting overproduction of the immune protein Type 1 interferon. Where earlier attempts of blocking this protein in lupus failed, there this potential new treatment, anifrolumab worked wonders by blocking the receptors on all the body’s cells, with the aim to reverse the triggering of lupus symptoms.
Besides, there might be a possibility of utilizing anifrolumab in the diagnosis of other interferon related diseases as interferon is associated with other autoimmune diseases as well.
In the trial, TULIP 2, eligible patients got a fixed-dose intravenous infusion of placebo or anifrolumab every four weeks. The trial evaluated the anifrolumab’s effect in minimizing disease activity.
Around 362 patients were involved in the trial that took place from 2015-2018, who received either 300mg of the drug or a placebo once every four weeks intravenously for 48 weeks. The benefit was calculated by using a defined clinical assessment of improvement in all the organs and the number of flare-ups.
After 52 weeks of trial, researchers found that the majority of patients on the drug than the placebo saw a reduction in the overall disease activity in all the active organs. Moreover, improvement in lupus skin disease, reduction in steroid drug doses, and reduction in the annual rate of flares were also noticed.
The researchers are now planning to work with regulators for bringing anifrolumab, the potential new medicine, to the diseased patients.